Literature DB >> 19667335

Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes.

Carol L Shields1, Minoru Furuta, Archana Thangappan, Saya Nagori, Arman Mashayekhi, David R Lally, Cecilia C Kelly, Danielle S Rudich, Anand V Nagori, Oojwala A Wakade, Sonul Mehta, Lauren Forte, Andrew Long, Elaina F Dellacava, Bonnie Kaplan, Jerry A Shields.   

Abstract

OBJECTIVE: To determine the rate of metastasis of uveal melanoma on the basis of tumor thickness in millimeters.
METHODS: Retrospective medical record review.
RESULTS: The mean (median) patient age was 58 (59) years. A total of 8033 eyes were examined. Of the 285 eyes with iris melanoma, the mean tumor thickness was 2.7 mm and metastasis occurred in 0.5%, 4%, and 7% at 3, 5, and 10 years, respectively. Of the 492 eyes with ciliary body melanoma, the mean tumor thickness was 6.6 mm and metastasis occurred in 12%, 19%, and 33% at 3, 5, and 10 years, respectively. Of the 7256 eyes with choroidal melanoma, the mean tumor thickness was 5.5 mm and metastasis occurred in 8%, 15%, and 25% at 3, 5, and 10 years, respectively. For all uveal melanoma, metastasis at 5, 10, and 20 years was 6%, 12%, and 20% for small melanoma (0-3.0 mm thickness), 14%, 26%, and 37% for medium melanoma (3.1-8.0 mm), and 35%, 49%, and 67% for large melanoma (>8.0 mm). More specifically, metastasis per millimeter increment at 10 years was 6% (0-1.0 mm thickness), 12% (1.1-2.0 mm), 12% (2.1-3.0 mm), 16% (3.1-4.0 mm), 27% (4.1-5.0 mm), 28% (5.1-6.0 mm), 29% (6.1-7.0 mm), 41% (7.1-8.0 mm), 50% (8.1-9.0 mm), 44% (9.1-10.0 mm), and 51% (>10.0 mm). Clinical factors predictive of metastasis by multivariate analysis included increasing patient age, ciliary body location, increasing tumor diameter, increasing tumor thickness, having a brown tumor, and the presence of subretinal fluid, intraocular hemorrhage, or extraocular extension.
CONCLUSION: Increasing millimeter thickness of uveal melanoma is associated with increasing risk for metastasis.

Entities:  

Mesh:

Year:  2009        PMID: 19667335     DOI: 10.1001/archophthalmol.2009.208

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  159 in total

Review 1.  [New treatment options for iridociliary tumors].

Authors:  J M Mor; K R Koch; V Kakkassery; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2019-04       Impact factor: 1.059

2.  Differences in uveal melanomas between men and women from the British Isles.

Authors:  B E Damato; S E Coupland
Journal:  Eye (Lond)       Date:  2011-11-11       Impact factor: 3.775

3.  Jejunojejunal intussusception secondary to metastatic uveal melanoma after 11 years of remission.

Authors:  Hifza Waheed Butt; Sarthak Soin; Faisal Ali; Antoni Wojtkowski
Journal:  BMJ Case Rep       Date:  2019-06-22

4.  Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma.

Authors:  Hasan Danish; Matthew J Ferris; Ehsan Balagamwala; Jeffrey M Switchenko; Kirtesh R Patel; Maria Choudhary; Caroline Craven; Pia Mendoza; John Suh; Chris Bergstrom; Hans E Grossniklaus; Thomas M Aaberg; Arun Singh; Ian R Crocker; Mohammad K Khan
Journal:  Melanoma Res       Date:  2018-04       Impact factor: 3.599

5.  Association between traditional clinical high-risk features and gene expression profile classification in uveal melanoma.

Authors:  Brandon T Nguyen; Ryan S Kim; Maria E Bretana; Eric Kegley; Amy C Schefler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-28       Impact factor: 3.117

6.  CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA.

Authors:  Duncan E Berry; Amy C Schefler; Michael I Seider; Miguel Materin; Sandra Stinnett; Prithvi Mruthyunjaya
Journal:  Retina       Date:  2018-11-08       Impact factor: 4.256

7.  Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients With Small Choroidal Melanoma Managed by Plaque Radiotherapy.

Authors:  Carol L Shields; Kareem Sioufi; Archana Srinivasan; Maura Di Nicola; Babak Masoomian; Laura E Barna; Vladislav P Bekerman; Emil A T Say; Arman Mashayekhi; Jacqueline Emrich; Lydia Komarnicky; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2018-12-01       Impact factor: 7.389

Review 8.  Transhepatic therapies for metastatic uveal melanoma.

Authors:  David J Eschelman; Carin F Gonsalves; Takami Sato
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

9.  Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation.

Authors:  Eszter Szalai; Yi Jiang; Natasha M van Poppelen; Martine J Jager; Annelies de Klein; Emine Kilic; Hans E Grossniklaus
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

Review 10.  The pathology of ocular cancer.

Authors:  R C Eagle
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.